Bacterial lipoprotein (BLP)

Bacterial lipoproteins (BLPs) are a diverse class of membrane-anchored proteins found in both Gram-positive and Gram-negative bacteria, characterized by a lipid-modified N-terminal cysteine. They are essential for bacterial physiology, playing critical roles in cell wall structural integrity, nutrient acquisition, and signal transduction. In the context of human health, BLPs are potent pathogen-associated molecular patterns (PAMPs) recognized by the innate immune system through Toll-like receptor 2 (TLR2) heterodimers. Recognition of triacylated BLPs by TLR2/TLR1 or diacylated BLPs by TLR2/TLR6 triggers the NF-κB signaling pathway, leading to the production of pro-inflammatory cytokines. This interaction is vital for host defense but can also drive systemic inflammation and sepsis. Therapeutically, synthetic BLP analogs like Pam3CSK4 are used as vaccine adjuvants to enhance immune responses. Additionally, the biosynthetic enzymes responsible for BLP maturation, such as lipoprotein signal peptidase (LspA), are being targeted for the development of novel antibiotics like globomycin.

Other names

Braun's lipoproteinMurein-lipoproteinLipopeptideLppPathogen-associated molecular patternPeptidoglycan-associated lipoprotein (Pal)

Bacterial lipoproteins act as ligands for Toll-like receptor 2 (TLR2) complexes (TLR2/1 for triacylated and TLR2/6 for diacylated forms), triggering the NF-κB signaling pathway to induce pro-inflammatory cytokine production. In drug development, synthetic analogs serve as vaccine adjuvants, while inhibitors of lipoprotein processing enzymes like Lgt (diacylglyceryl transferase) and LspA (signal peptidase II) act as experimental antibiotics by causing the accumulation of toxic prolipoprotein precursors.